Aptamer Group grows sales pipeline to £7m as it targets break-even
Aptamer Group has increased revenues by 28% and grown its sales pipeline to £7m as the Yorkshire life sciences business looks to turn growing interest in its technology into sustainable profitability.
The AIM-listed company, which develops synthetic binders known as Optimers for use in drug discovery, diagnostics and other life sciences applications, reported revenues of £1.5m for the year to 30 June 2026, up from £1.2m a year earlier.
But the higher sales have yet to translate into improved earnings, with its adjusted EBITDA... You can carry on reading TheBusinessDesk.com for free, but you have reached the maximum number of pages an unregistered user can view. To register for an account, click here or login below...
